Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues

Bibliography

• ZHANG FL, CASEY PJ: Protein prenylation: molecular mechanisms and functional consequences. Ann. Rev. Biochem. (1996) 65:241–269.
   PubMed Web of Science ®Google Scholar
• •Excellent paper for protein prenylation.
   Google Scholar
• CASEY PJ: Biochemistry of protein prenylation. j Lipid Res. (1992) 33(12):1731–1740.
   PubMed Web of Science ®Google Scholar
• REISS Y, GOLDSTEIN JL, SEABRA MC, CASEY PJ, BROWN MS: Inhibition of purified p21 ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell (1990) 62 (1) :81–88.
   PubMed Web of Science ®Google Scholar
• ••First paper to demonstrate importance of CAAX box asFTase recognition site.
   Google Scholar
• BARBACID M: Ras genes. Ann. Rev. Biochem. (1987) 56:779–827.
   PubMed Web of Science ®Google Scholar
• BARBACID M: Human oncogenes. Important Adv. Oncol (1986):3–22.
   PubMedGoogle Scholar
• ZOHN IM, CAMPBELL SL, KHOSRAVI-FAR R, ROSSMAN KL, DER CJ: Rho family proteins and Ras transformation: the RHOad less travelled gets congested. Oncogene (1998) 17 (11) :1415–1438 .
   PubMedGoogle Scholar
• •Excellent review for Rho protein and transformation.
   Google Scholar
• SEBTI S, HAMILTON AD: Anticancer activity of farnesyl-transferase and geranylgeranyltransferase I inhibi-tors: prospects for drug development. Exp. Opin. Invest. Drugs (1997) 6(10:1711–1714.
   PubMedGoogle Scholar
• SEBTI SM, HAMILTON AD: Farnesyltransferase and geranylgeranyltransferase I inhibitors as novel agents for cancer and cardiovascular diseases. In: Farnesyl-transferase Inhibitors in Cancer Therapy. Sebti SM, Hamilton AD (Eds.), Humana Press, Inc., Totowa, NJ, USA (2000).
   Google Scholar
• COX AD, DER CJ: Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta (1997) 1333 (1):F51–71.
   PubMed Web of Science ®Google Scholar
• GIBBS JB, OLIFF A: The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Ann. Rev. Pharmacol. Toxicol. (1997) 37:143–166.
   PubMed Web of Science ®Google Scholar
• SEBTI SM, HAMILTON AD: Inhibition of Ras prenyla-tion: a novel approach to cancer chemotherapy. Pharmacol. Ther. (1997) 74 (1) :103–114.
   PubMed Web of Science ®Google Scholar
• SUN J, BLASKOVICH MA, KNOWLES D et al.: Antitumourefficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol and gemcita-bine. Cancer Res. (1999) 59(19)4919–4926.
   Google Scholar
• •Demonstration of the benefits of combining FTIs with cytotoxic agents.
   Google Scholar
• SEBTI SM, HAMILTON AD: Farnesyltransferase geranylgeranyltransferase I: targets for cancer cardiovascular therapy. In: Farnesyltransferase Inhibitors and and in Cancer Therapy. Sebti SM, Hamilton AD (Eds.), Humana Press, Inc., Totowa, NJ, USA (2000).
   Google Scholar
• LERNER EC, QIAN Y, HAMILTON AD, SEBTI SM: Disrup-tion of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol. Chem. (1995) 270 (45):26770–26773.
   PubMed Web of Science ®Google Scholar
• LERNER EC, ZHANG TT, KNOWLES DB, QIAN Y, HAMILTON AD, SEBTI SM: Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyl-transferase and a geranylgeranyltransferase I inhibitor in human tumour cell lines. Oncogene (1997) 15(10:1283–1288.
   PubMedGoogle Scholar
• ••First demonstration that inhibition of K-Ras prenylationrequires both FTIs and GGTIs.
   Google Scholar
• NIGAM M, SEONG CM, QIAN Y, HAMILTON AD, SEBTI SM: Potent inhibition of human tumour p21ras farnesyl-transferase by A1A2- lacking p21ras CA1A2X peptidomimetics. J Biol. Chem. (1993) 2 6 8 (28):20695–20698.
   Google Scholar
• QIAN Y, BLASKOVICH MA, SEONG C-M, VOGT A, HAMILTON AD, SEBTI SM: Pep tidomim etic inhibitors of p21ras farnesyltransferase: hydrophobic functionali-zation leads to disruption of p21ras membrane association in while cells. Bioorg. Med. Chem. Lett. (1994) 4:2579–2584.
   Web of Science ®Google Scholar
• LERNER EC, QIAN Y, BLASKOVICH MA et al: Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. j Biol. Chem. (1995) 270 (45):26802–26806.
   PubMed Web of Science ®Google Scholar
• MCGUIRE TF, QIAN Y, VOGT A, HAMILTON AD, SEBTI SM: Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranyla-tion but not farnesylation. J. Biol. Chem. (1996) 271 (44):27402–27407.
   PubMed Web of Science ®Google Scholar
• VOGT A, QIAN Y, MCGUIRE TF, HAMILTON AD, SEBTI SM: Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene (1996) 13(9):1991–1999.
   PubMed Web of Science ®Google Scholar
• JAMES GL, GOLDSTEIN JL, BROWN MS: Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. (1995) 270(10:6221–6226.
   PubMedGoogle Scholar
• WHYTE DB, KIRSCHMEIER P, HOCKENBERRY TN et al: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol. Chem. (1997) 272(22):14459–14464.
   PubMed Web of Science ®Google Scholar
• ••Critical demonstration of alternative geranylgeranylation ofK-Ras when FTase is inhibited in human cancer cells.
   Google Scholar
• ROWELL CA, KOWALCZYK JJ, LEWIS MD, GARCIA AM: Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem. (1997) 272 (22):14093–14097.
   PubMed Web of Science ®Google Scholar
• ••Critical demonstration of alternative geranylgeranylation ofK-Ras when FTase is inhibited in human cancer cells.
   Google Scholar
• SUN J, QIAN Y, HAMILTON AD, SEBTI SM: Both farnesyl- transferase and geranylgeranyltransferase I inhibi-tors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumour growth in nude mouse xenografts. Oncogene (1998) 1 6 (1 0 :1467–1473.
   Google Scholar
• •Demonstration that inhibition of K-Ras prenylation is not required for inhibition of tumour growth in vivo.
   Google Scholar
• SUN J, QIAN Y, HAMILTON AD, SEBTI SM: Ras CAAX peptidomimetic FTI 276 selectively blocks tumour growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res. (1995) 55 (19):4243–4247.
   PubMed Web of Science ®Google Scholar
• •Demonstration that FTIs inhibit growth of human tumours with multiple genetic alterations.
   Google Scholar
• BREDEL M, POLLACK IF, FREUND JM, HAMILTON AD, SEBTI SM: Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth. Neurosurgery (1998) 43 (1) :124–131.
   PubMed Web of Science ®Google Scholar
• POLLACK IF, BREDEL M, ERFF M, HAMILTON AD, SEBTI SM: Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II-preclinical studies in a nude mouse model. Neurosur-gery (1999) 45 (5) :1208–1214.
   PubMed Web of Science ®Google Scholar
• KHOSRAVI-FAR R, SOLSKI PA, CLARK GJ, KINCH MS, DER CJ: Activation of Rac1, RhoA and mitogen-activated protein kinases is required for Ras transformation. Mol. Cell Biol. (1995) 15 (1 1) :6443–6453.
   Google Scholar
• QIU RG, CHEN J, MCCORMICK F, SYMONS M: A role for Rho in Ras transformation. Proc. Natl. Acad. ScL USA (1995) 92(25):11781–11785.
   PubMed Web of Science ®Google Scholar
• GIBBS JB, GRAHAM SL, HARTMAN GD et al.: Antitumour efficacy of a farnesyltransferase inhibitor in transgenic mice. In: Farnesyltransferase Inhibitors in Cancer Therapy. Hamilton AD (Ed.), Humana Press, Inc., Totwa, NJ, USA (2000):65–70.
   Google Scholar
• ••Excellent review about the ability of FTIs to induce tumourregression in transgenic mice.
   Google Scholar
• OMER CA, CHEN Z, DIEHL RE et al.: Mouse mammary tumour virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res. (2000) 60(10)2680–2688.
   Google Scholar
• KAUFFMANN RC, QIAN Y, VOGT A, SEBTI SM, HAMILTON AD, CARTHEW RW: Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors. Proc. Natl. Acad. ScL USA (1995) 92(24)10919–10923.
   Google Scholar
• LANTRY LE, ZHANG Z, YAO R et al.: Effect of farnesyl- transferase inhibitor FTI-276 on established lung adenomas from A4 mice induced by 4-(methylnitro-samin 0)-1 -(3 -pyridy1)-1 -butanone. Carcinogenesis (2000) 21 (0:113–116.
   PubMedGoogle Scholar
• •Demonstration that FTIs can inhibit/prevent carcinogen-induced tumours.
   Google Scholar
• BERNHARD EJ, KAO G, COX AD et al.: The farnesyltrans- ferase inhibitor FTI-277 radiosensitizes H-r as-transformed rat embryo fibroblasts. Cancer Res. (1996) 56(01727–1730.
   PubMed Web of Science ®Google Scholar
• BERNHARD EJ, MCKENNA WG, HAMILTON AD et al: Inhibiting Ras prenylation increases the radiosensi-tivity of human tumour cell lines with activating mutations of ras oncogenes. Cancer Res. (1998) 58(8):1754–1761.
   PubMed Web of Science ®Google Scholar
• SEPP-LORENZINO L, MA Z, RANDS E et al.: A p eptidomi-metic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumour cell lines. Cancer Res. (1995) 55 (22):5302–5309.
   PubMed Web of Science ®Google Scholar
• NAGASU T, YOSHIMATSU K, ROWELL C, LEWIS MD, GARCIA AM: Inhibition of human tumour xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. (1995) 55(22):5310–5314.
   PubMed Web of Science ®Google Scholar
• PRENDERGAST GC, DAVIDE JP, DESOLMS SJ et al.: Farnesyltransferase inhibition causes morphological reversion of ras- transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell Biol. (1994) 1 4 (6):4193–4202.
   Google Scholar
• YAN J, ROY S, APOLLONI A, LANE A, HANCOCK JF: Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J. Biol. Chem. (1998) 273(37)24052–24056.
   Google Scholar
• VOICE JK, KLEMKE RL, LE A, JACKSON JH: Four human ras homologs differ in their abilities to activate Raf-1, induce transformation and stimulate cell motility. J Biol. Chem. (1999) 27 4 (2017164–17170.
   Google Scholar
• LEBOWITZ PF, CASEY PJ, PRENDERGAST GC, THISSEN JA: Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J. Biol. Chem. (1997) 272(25):15591–15594.
   PubMed Web of Science ®Google Scholar
• ZALCMAN G, CLOSSON V, LINARES-CRUZ G etal.: Regula-tion of Ras-related RhoB protein expression during the cell cycle. Oncogene (1995) 1 0 (10):1935–1945.
   Google Scholar
• LEBOWITZ PF, DAVIDE JP, PRENDERGAST GC: Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol. Cell Biol. (1995) 15(12):6613–6622.
   PubMed Web of Science ®Google Scholar
• •Evidence for RhoB as a target for FTIs.
   Google Scholar
• SHIH TY, STOKES PE, SMYTHERS GW, DHAR R, OROSZLAN S: Characterization of the phosphorylation sites and the surrounding amino acid sequences of the p21 transforming proteins coded for by the Harvey and Kirsten strains of murine sarcoma viruses. J Chem. (1982) 257(19):11767–11773.
   Google Scholar
• DU W, PRENDERGAST GC: Geranylgeranylated RhoB mediates suppression of human tumour cell growth by farnesyltransferase inhibitors. Cancer Res. (1999) 59(205492–5496.
   Google Scholar
• LIU A, DU W, LIU JP, JESSELL TM, PRENDERGAST GC: RhoB alteration is necessary for apop to tic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell. Biol. (2000) 20 (16):6105–6113.
   PubMed Web of Science ®Google Scholar
• CHEN Z, SUN J, PRADINES A, FAVRE G, ADNANE J, SEBTI SM: Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumour growth in nude mice. J. Biol. Chem. (2000) 275 (2017974–17978.
   Google Scholar
• •Evidence against RhoB as a target for FTIs.
   Google Scholar
• ADAMSON P, MARSHALL CJ, HALL A, TILBROOK PA: Post-translational modifications of p21rho proteins. J. Biol. Chem. (1992) 267 (28):20033–20038.
   PubMed Web of Science ®Google Scholar
• LEBOWITZ PF, SAKAMURO D, PRENDERGAST GC: Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res. (1997) 57(4):708–713.
   PubMed Web of Science ®Google Scholar
• SUZUKI N, URANO J, TAMANOI F: Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc. Nati Acad. Sci. USA (1998) 95(26):15356–15361.
   PubMed Web of Science ®Google Scholar
• JIANG K, COPPOLA D, CRESPO NC et al.: The phosphoi-nositide 3-0Hkinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell Biol. (2000) 20(0:139–148.
   PubMedGoogle Scholar
• ••Evidence for the PI3K-Akt pathway as a critical target forFTI-induced apoptosis.
   Google Scholar
• DU W, LIU A, PRENDERGAST GC: Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res. (1999) 59 (17):4208–4212.
   PubMed Web of Science ®Google Scholar
• VOGT A, SUN J, QIAN Y, HAMILTON AD, SEBTI SM: The ger anylgeranyltransferase-I inhibitor GGTI-298 arrests human tumour cells in G0/G1 and induces p21 (WAFI /CIP1/SDI1) in a p53-independent manner. J. Biol. Chem. (1997) 272 (43):27224–27229.
   PubMed Web of Science ®Google Scholar
• SEPP-LORENZINO L, ROSEN N: A farnesyl-protein transferase inhibitor induces p21 expression and GI block in p53 wild type tumour cells. j Biol. Chem. (1998) 273 (32):20243–20251.
   PubMed Web of Science ®Google Scholar
• ASHAR HR, JAMES L, GRAY K et al.: FTIs block thefarnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. j Biol. Chem. (2000) 275(39):30451–30457.
   PubMed Web of Science ®Google Scholar
• CRESPO N, OHKANDA J, YEN T, HAMILTON AD, SEBTISM: The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. j Biol. Chem. (2000). (In Revision).
   Google Scholar
• LEE J, MIYANO T, DAI Y, WOODING P, YEN TJ, MOOR RM: Specific regulation of CENP-Eandkinetochores during meiosis I/meiosis II transition in pig oocytes. Mol Reprod. Dev. (2000) 56(0:51–62.
   PubMedGoogle Scholar
• ADNANE J, BIZOUARN FA, QIAN Y, HAMILTON AD, SEBTI SM: p21(WAFI/CIP1) is upregulated by the geranyl-geranyltransferase I inhibitor GGTI-298 through a transforming growth factor-I3- and Sp1-responsive element: involvement of the small GTPase rhoA. Mol Cell Biol (1998) 18(12)6962–6970.
   Google Scholar
• OLSON MF, PATERSON HF, MARSHALL CJ: Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature (1998) 394(6690):295–299.
   PubMed Web of Science ®Google Scholar
• SUN J, QIAN Y, CHEN Z, MARFURT J, HAMILTON AD,SEBTI SM: The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retino-blastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumour activity. J. Biol. Chem. (1999) 274 (1 1) :6930–6934.
   Google Scholar
• ZUJEWSKI J, HORAK ID, BOL CJ et al.: Phase I andpharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. (2000) 18(4):927–941.
   PubMed Web of Science ®Google Scholar
• HUDES GR, SCHOL J, BAAB et al: Phase I clinical andph armacokin etic trial of the farnesyltrnasferase inhibitor R115777 on a 21-day dosing schedule. Proc. Am. Soc. Clin. Oncol. (1999) 18:601.
   Google Scholar
• LANCET JE, ROSENBLATT JD, LIESVELD JL et al: Use offarnesyltransferase inhibitor R155777 in relapsed and refractory acute leukemias: Preliminary results of Phase I trial. Proc. Am. Soc. Clin. Oncol. (2000) 19.
   Google Scholar
• ADJEI AA, ERLICHMAN C, DAVIS JN et al.: A Ph ase I trial ofthe farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. (2000) 60(7):1871–1877.
   PubMed Web of Science ®Google Scholar
• HURWITZ HI, AMADO R, PRAGER D et al: Phase I ph armacokin etic trial of the farnesyltransferase inhibitors SCH66336 plus gemcitabine in advanced cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19.
   Google Scholar
• ESKENS F, AWADA A, VERWEIJ et al.: Phase I andpharmacologic study of continuous daily oral SCH-66336, a novel farnesyl transferase inhibitor, in patients with solid tumours. Proc. Am. Soc. Clin. Oncol. (1999) 18:600.
   Google Scholar
• SOIGNET S, YAO S-L, BRITTEN D et al.: Pharmacoki-netics and pharmacodynamics of the farnesyl protein transferase inhibitor (L-778,123) in solid tumours. Proc. Am. Assoc. Can. Res. (1998) 40:517.
   Google Scholar
• BRITTEN CD, ROWINSKY E, YAO S-L et al.: A Phase land pharmacologic study of the farnesyl protein transfe-rase inhibitor L-778,123 in patients with solid cancers. Proc. Am. Soc. Clin. Oncol. (1999) 18:597.
   Google Scholar
• RYAN DP, EDER JP, SUPKO JG et al.: Phase I Clinical Trial of Farnesyltransferase (FT) Inhibitor BMS-214662 in Patients with Advanced Solid Tumours. ASCO Annual Meeting. New Orleans, LA, USA (2000).
   Google Scholar
• PATNAIK A, ROWINSKY EK: Early clinical experience with farnesyl protein transferase inhibitors: from the bench to the bedside. In: Farnesyltransferase Inhibitors in Cancer Therapy. Hamilton AD (Ed.), Humana Press, Inc., Totowa, NJ, USA (2000233–249.
   Google Scholar
• •Excellent review about clinical experience with FTIs.
   Google Scholar
• KHURI FR, GLISSON BS, MEYERS ML et al.: Phase I study of farnesyl transferase inhibitor (1,11) 5CH66336 with paclitaxel in solid tumours: Dose finding, pharma-cokinetics, efficacy/safety. Proc. Am. Soc. Clin. Oncol (2000) 19.
   Google Scholar
• HAHN SM, KIEL K, MORRISON BW et al.: Phase I trial of the farnesyl protein transferase (FPTase) inhibitor L-778123 in combination with radiotherapy. Proc. Am. Soc. Clin. Oncol (2000) 19.
   Google Scholar
• ROBINET G, THOMAS P, PEROL M et al.: Phase II study of docetax el in inoperable advanced non-small cell lung cancer. Bull. Cancer (2000) 87(3):253–258. Said M Sebtit & Andrew D Hamilton
   Google Scholar